Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 3/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.50 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | TPMT | P51580 | 1/20 | 0.42 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11377331 | 0.84 | MAPK1 (0.59) | MAPK1MAPTPOLBL3MBTL1OPRK1 | |
| SCHEMBL710164 | 0.84 | NPC1 (0.53) | MAPK1MAPTPOLBKDM4EKMT2A | |
| SCHEMBL18038271 | 0.83 | MAPK1 (0.57) | MAPK1MAPTPOLBL3MBTL1OPRK1 | |
| SCHEMBL72992 | 0.83 | MAPT (0.57) | MAPK1MAPTPOLBL3MBTL1OPRK1 | |
| SCHEMBL31440674 | 0.83 | MAPT (0.57) | MAPK1MAPTPOLBL3MBTL1OPRK1 | |
| SCHEMBL4662535 | 0.82 | MAPT (0.64) | MAPK1MAPTPOLBL3MBTL1OPRK1 | |
| SCHEMBL40980 | 0.82 | MAPT (0.50) | MAPK1MAPTPOLBL3MBTL1OPRK1 | |
| SCHEMBL13285512 | 0.82 | MAPK1 (0.56) | MAPK1MAPTPOLBL3MBTL1OPRK1 | |
| SCHEMBL72187 | 0.82 | MAPT (0.56) | MAPK1MAPTPOLBL3MBTL1OPRK1 | |
| SCHEMBL18227400 | 0.82 | MAPK1 (0.56) | MAPK1MAPTPOLBL3MBTL1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108602812-B | Bicyclic hydroxamic acids useful as inhibitors of histone deacetylase activity in mammals | 坎塞拉有限公司 | 2021-11-02 | — | — | CN | disclosed |
| EP-3394052-B1 | BICYCLIC HYDROXAMIC ACIDS USEFUL AS INHIBITORS OF MAMMALIAN HISTONE DEACETYLASE ACTIVITY | KANCERA AB (SE) | 2021-07-28 | — | — | EP | disclosed |
| US-10654814-B2 | Bicyclic hydroxamic acids useful as inhibitors of mammalian histone deacetylase activity | KANCERA AB (SE) | 2020-05-19 | — | — | US | disclosed |
| US-20190284147-A1 | BICYCLIC HYDROXAMIC ACIDS USEFUL AS INHIBITORS OF MAMMALIAN HISTONE DEACETYLASE ACTIVITY | KANCERA AB (SE) | 2019-09-19 | — | — | US | disclosed |
| WO-2019049061-A1 | 5-(1 H-BENZO[D]IMIDAZO-2-YL)-PYRIDIN-2-AMINE AND 5-(3H-IMIDAZO[4,5-B]PYRIDIN-6-YL)-PYRIDIN-2-AMINE DERIVATIVES AS C-MYC AND P300/CBP HISTONE ACETYLTRANSFERASE INHIBITORS FOR TREATING CANCER | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-03-14 | — | — | WO | disclosed |
| EP-3394052-A1 | BICYCLIC HYDROXAMIC ACIDS USEFUL AS INHIBITORS OF MAMMALIAN HISTONE DEACETYLASE ACTIVITY | Kancera AB (SE) | 2018-10-31 | — | — | EP | disclosed |
| EP-2714660-B1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2018-09-26 | — | — | EP | disclosed |
| US-20180105503-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-04-19 | — | — | US | disclosed |
| US-20180105503-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-04-19 | — | — | US | disclosed |
| US-9938261-B2 | Heterocyclic compounds and methods of use thereof | AMBIT BIOSCIENCES CORPORATION (US) | 2018-04-10 | — | — | US | disclosed |
| US-6313137-B1 | FOR THERAPY AND PROPHYLAXIS OF GASTROINTESTINAL INFLAMMATORY DISEASES | ASTRAZENECA AB (SE) | 2001-11-06 | — | — | US | disclosed |
| EP-0399731-B2 | Azaindenes | ASTRAZENECA AB (SE) | 2001-07-11 | — | — | EP | disclosed |
| EP-1073657-A1 | IMIDAZO PYRIDINE DERIVATIVES WHICH INHIBIT GASTRIC ACID SECRETION | AstraZeneca AB (SE) | 2001-02-07 | — | — | EP | disclosed |
| WO-1999055706-A9 | IMIDAZO PYRIDINE DERIVATIVES WHICH INHIBIT GASTRIC ACID SECRETION | ASTRA AB (SE) | 2000-03-16 | — | — | WO | disclosed |
| WO-1999055706-A1 | IMIDAZO PYRIDINE DERIVATIVES WHICH INHIBIT GASTRIC ACID SECRETION | ASTRAZENECA AB (SE) | 1999-11-04 | — | — | WO | disclosed |
| EP-0399731-B1 | Azaindenes | ZENECA LTD (GB) | 1993-12-08 | — | — | EP | disclosed |
| EP-0399731-A1 | Azaindenes | ZENECA LIMITED (GB) | 1990-11-28 | — | — | EP | disclosed |
| US-4880815-A | GASTRIC JUICE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1989-11-14 | — | — | US | disclosed |
| US-4738970-A | Benzimidazolyl-thio-tetrahydroquinolines and anti-peptic ulcer compositions containing the same | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1988-04-19 | — | — | US | disclosed |
| EP-0187977-A1 | Tetrahydroquinoline derivatives, process for preparing the same and anti-peptic ulcer compositions containg the same | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1986-07-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10654814-B2 | Bicyclic hydroxamic acids useful as inhibitors of mammalian histone deacetylase activity | HDAC1, HDAC11, HDAC10 | MAPK1 847/4885MAPT 1282/4885POLB 59/4885 |
| US-20190284147-A1 | BICYCLIC HYDROXAMIC ACIDS USEFUL AS INHIBITORS OF MAMMALIAN HISTONE DEACETYLASE ACTIVITY | HDAC1, HDAC11, HDAC10 | MAPK1 847/4885MAPT 1282/4885POLB 59/4885 |
| US-20180105503-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | MAPK1 1229/4885MAPT 484/4885POLB 2844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.